Drugs / Desiccated Thyroid Extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07239674 | Nov 2025 → Nov 2027 expected | differentiated thyroid carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| — | NCT02317926 Comparator | May 2015 → May 2018 | hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT01739972 Comparator | May 2012 → May 2014 | peripheral hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | desiccated thyroid extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07239674 ↗ |
| Known as | DTE | “Desiccated thyroid extract (DTE) is a dry preparation obtained from animal thyroid glands that contains both thyroxine (T4) and triiodothyronine (T3) in an approximately 4:1...” NCT07239674 ↗ |